Pfizer last week announced that the Food and Drug Administration has granted fast track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090).
A study published earlier this week in the journal Pediatrics determined that the probiotic Lactobacillus reuteri helped substantially reduce episodes of diarrhea and respiratory tract infections among children in a daycare setting.
The majority of pediatric bacterial infections that cause severe diarrhea and are potentially life-threatening occur among children who recently took antibiotics prescribed by doctors for other conditions, according to a new study by the Centers for Disease Control and Prevention published this week in Pediatrics.
Reckitt Benckiser, whose portfolio includes such brands as Clearasil, Mucinex and Lysol, is partnering with Save the Children to help drastically lower the global death rate of children younger than 5 years from diarrhea, a preventable illness, by 2020.
Among children who took part in a recent study on the use of hand sanitizer in an environment with limited access to clean water, diarrhea cases were reduced by 30% and respiratory illnesses by more than 11%, GOJO Industries noted in a release issued Tuesday.
Consumption of probiotics is associated with a reduced risk of antibiotic-associated diarrhea, a common adverse effect of antibiotic use, according to a review and meta-analysis of previous studies published in the May 9 issue of JAMA, the Journal of the American Medical Association.
The Food and Drug Administration on Wednesday issued a public warning that the use of proton-pump inhibitors or H2 blockers may be associated with an increased risk of Clostridium difficile–associated diarrhea, or CDAD.